You are now leaving hcp.osphena.com and proceeding to Osphena.ca

Osphena.ca is intended for Canadian healthcare professionals. If you are a Canadian healthcare professional, click “I Agree” to continue.

I Agree

Menopause should be liberating, not irritating When VVA symptoms disrupt a patient’s life, it could be time for Osphena®1,2

Once-daily Osphena® is the first and only treatment for moderate to severe vaginal dryness and/or dyspareunia that is non-hormonal, comes in an oral tablet and acts locally to improve the condition of specific vaginal tissue.*,3,4

*Increases superficial cells, decreases parabasal cells, and reduces vaginal pH.

Help your patients save through Osphena® Savings Programs

Patients with commercial insurance pay as little as $35 for 30 tablets or $90 for 90 tablets witht the Osphena At Home® program.

Savings options are also available for patients who do not have prescription insurance or whose insurance does not cover Osphena®.

Learn more about Osphena® Savings Options

Hypothetical Healthcare Professional.
Option 1

Option 1 - Mail Order Pharmacy

Osphena At Home® program offers the lowest price regardless of coverage

If your patient has commercial insurance

Pay as little as

$35*for 30 tablets

or

$90*for 90 tablets

If your patient's insurance does not cover Osphena® or they do not have insurance:

$190*

for 90 tabletsper prescription

Prescribe Osphena(R) through Osphena At Home(R) for patients to receive additional services including:

Free Home delivery

On-staff pharmacists to answer
product questions

Assistance with insurance
benefit verification

Monthly refill reminders

Questions? Call (844) 716-HOME (4663)

*See terms and conditions

Download Osphena At Home® Patient Instructions

Download Osphena At Home® Patient Instructions – Spanish/Español

ic savings white
Option 2

Retail Pharmacy

Osphena® Savings Card

If your patient has commercial insurance

Pay as little as

$45*for 30 tablets

Questions? Call (347) 657-9766

Apollo Care Processing Information:

Bin: 637765

Group ID: 99992002

RxPCN: CRX

#ID: 46611500801

 

If your patient's insurance does not cover Osphena® or they do not have insurance:

GoodRx logo GoodRx Savings Offer

Pay as little as:

  • $2.28*

    /tablet for > 60 tablets**

  • $85*

    for 30 tablets (1 month supply)

  • $205*

    for 90 tablets (3 month supply)

GoodRx Processing Information

Bin: 610020

Group ID: 99995428

RxPCN: PDM

#ID: EROXOSPHENA

GoodRx is NOT insurance. Cancel anytime. By continuing, you agree to the GoodRx Terms of Use and Privacy Policy available at goodrx.com/terms. ©2025 GoodRx, Inc., 2701 Olympic Blvd., Santa Monica, CA 90404.

*See terms and conditions

**Price per tablet may vary for quantities less than 60 tablets

Download Savings Card

Help your patients save through Osphena® Savings Programs

Patients with commercial insurance pay as little as $35 for 30 tablets or $90 for 90 tablets witht the Osphena At Home® program.

Savings options are also available for patients who do not have prescription insurance or whose insurance does not cover Osphena®.

Learn more about Osphena® Savings Options

Option 2

Retail Pharmacy

Osphena® Savings Card

If your patient has commercial insurance

Pay as little as

$45*for 30 tablets

Questions? Call (347) 657-9766

Apollo Care Processing Information:

Bin: 637765

Group ID: 99992002

RxPCN: CRX

#ID: 46611500801

 

If your patient's insurance does not cover Osphena® or they do not have insurance:

GoodRx logo GoodRx Savings Offer

Pay as little as:

  • $2.28*

    /tablet for > 60 tablets**

  • $85*

    for 30 tablets (1 month supply)

  • $205*

    for 90 tablets (3 month supply)

GoodRx Processing Information

Bin: 610020

Group ID: 99995428

RxPCN: PDM

#ID: EROXOSPHENA

GoodRx is NOT insurance. Cancel anytime. By continuing, you agree to the GoodRx Terms of Use and Privacy Policy available at goodrx.com/terms. ©2025 GoodRx, Inc., 2701 Olympic Blvd., Santa Monica, CA 90404.

*See terms and conditions

**Price per tablet may vary for quantities less than 60 tablets

Download Savings Card

Option 1

Option 1 - Mail Order Pharmacy

Osphena At Home® program offers the lowest price regardless of coverage

If your patient has commercial insurance

Pay as little as

$35*for 30 tablets

or

$90*for 90 tablets

If your patient's insurance does not cover Osphena® or they do not have insurance:

$190*

for 90 tabletsper prescription

Prescribe Osphena(R) through Osphena At Home(R) for patients to receive additional services including:

Free Home delivery

On-staff pharmacists to answer
product questions

Assistance with insurance
benefit verification

Monthly refill reminders

Questions? Call (844) 716-HOME (4663)

*See terms and conditions

Download Osphena At Home® Patient Instructions

Download Osphena At Home® Patient Instructions – Spanish/Español

Osphena® is affordable and accessible Several Ways For Patients to Save on Osphena®

Osphena® is affordable and accessible Several Ways For Patients to Save on Osphena®

Indication and Important Safety Information including Boxed Warning

INDICATIONS:

OSPHENA (ospemifene) is indicated for:

  • The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
  • The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause.

Important Safety Information for OSPHENA

WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS

See full prescribing information for complete boxed warning

Endometrial Cancer

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Perform adequate diagnostic measures, including directed and random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Cardiovascular Disorders

Estrogen-alone therapy has an increased risk of stroke and deep vein thrombosis (DVT). OSPHENA 60 mg had cerebral thromboembolic and hemorrhagic stroke incidence rates of 1.13 and 3.39 per thousand women years, respectively vs. 3.15 and 0 per thousand women years, respectively with placebo. For deep vein thrombosis the incidence rate for OSPHENA 60 mg is 2.26 per thousand women years (2 reported cases) vs. 3.15 per thousand women years (1 reported case) with placebo.

CONTRAINDICATIONS

  • Undiagnosed abnormal genital bleeding
  • Estrogen-dependent neoplasia
  • Active deep vein thrombosis (DVT), pulmonary embolism (PE), or a history of these conditions
  • Active arterial thromboembolic disease (e.g., stroke and myocardial infarction) or a history of these conditions
  • Hypersensitivity (e.g., angioedema, urticaria, rash, pruritus) to OSPHENA or any ingredients
  • OSPHENA is contraindicated in women who are or may become pregnant. OSPHENA may cause fetal harm when administered to a pregnant woman.

WARNINGS AND PRECAUTIONS

Cardiovascular Disorders

Manage appropriately any risk factors for cardiovascular disorders, arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus).

If feasible, discontinue OSPHENA at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism or during periods of prolonged immobilization.

Malignant Neoplasms

Endometrial Cancer

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has agonistic effects. 

An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The greatest risk appears to be associated with prolonged use and estrogen dose. Adding a progestin to postmenopausal estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.

Breast Cancer

OSPHENA 60 mg has not been adequately studied in women with breast cancer; therefore, it should not be used in women with known or suspected breast cancer or with a history of breast cancer.

Severe Hepatic Impairment

OSPHENA should not be used in women with severe hepatic impairment.

Adverse Reactions

The most common adverse reactions (> 1%) with OSPHENA are: hot flush, vaginal discharge, muscle spasms, headache, hyperhidrosis, vaginal hemorrhage, night sweats.

Drug interactions:

  • Do not use estrogens or estrogen agonist/antagonist concomitantly with OSPHENA.
  • Do not use fluconazole or ketoconazole concomitantly with OSPHENA.
  • Do not use rifampin concomitantly with OSPHENA. Rifampin decreases serum concentrations of OSPHENA.

Co-administration of OSPHENA with drugs that inhibit CYP3A4 and CYP2C9 may increase the risk of OSPHENA-related adverse reactions. OSPHENA is highly protein-bound. Use cautiously with highly protein-bound drugs as use with other highly protein-bound drugs may lead to increased exposure of that drug or ospemifene.

Please see Full Prescribing Information for OSPHENA (ospemifene) tablets, including Boxed Warning regarding Endometrial Cancer and Cardiovascular Disorders, and Patient Information at osphena.com/hcp.

INDICATION AND IMPORTANT SAFETY INFORMATION FOR HEALTH CARE PROFESSIONALS

 

INDICATION:

OSPHENA (ospemifene) is indicated for:

  • The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
  • The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause

Important Safety Information for OSPHENA

WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS

Endometrial Cancer

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Perform adequate diagnostic measures, including directed and random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Cardiovascular Disorders

Estrogen-alone therapy has an increased risk of stroke and deep vein thrombosis (DVT). OSPHENA 60 mg had cerebral thromboembolic and hemorrhagic stroke incidence rates of 1.13 and 3.39 per thousand women years, respectively vs. 3.15 and 0 per thousand women years, respectively with placebo. For deep vein thrombosis the incidence rate for OSPHENA 60 mg is 2.26 per thousand women years (2 reported cases) vs. 3.15 per thousand women years (1 reported case) with placebo.

INDICATION AND IMPORTANT SAFETY INFORMATION FOR HEALTH CARE PROFESSIONALS

 

INDICATION:

OSPHENA (ospemifene) is indicated for:

  • The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
  • The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause

Important Safety Information for OSPHENA

WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS

Endometrial Cancer

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Perform adequate diagnostic measures, including directed and random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Cardiovascular Disorders

Estrogen-alone therapy has an increased risk of stroke and deep vein thrombosis (DVT). OSPHENA 60 mg had cerebral thromboembolic and hemorrhagic stroke incidence rates of 1.13 and 3.39 per thousand women years, respectively vs. 3.15 and 0 per thousand women years, respectively with placebo. For deep vein thrombosis the incidence rate for OSPHENA 60 mg is 2.26 per thousand women years (2 reported cases) vs. 3.15 per thousand women years (1 reported case) with placebo.